Healthcare Industry News: IPLEX
News Release - September 10, 2008
Plexigen, Inc. Announces the Appointment of Bill Haas as President and CEONew Executive Joins the Diagnostic Platform Company to Lead the Commercialization of their New Microarray, High-throughput MultIPLEX Instrument, the PlexStation 2080
CARY, N.C.--(HSMN NewsFeed)--“We are very excited to have Bill Haas join Plexigen at this critical premarket point.” says Founder and Chief Scientific Officer, Ben Liu, PhD. “Bill spent eighteen years at Laboratory Corporation of America, Inc., in many dynamic roles, most recently as their Executive Vice President, Esoteric Business. This broad expertise will contribute significantly to Plexigen's future success.”
“The immediate focus of the company is to attain FDA 510(k) clearance for the PlexStation 2080 and the initial assays, while readying the Plexigen organization for the commercialization phase of our high-potential IVD technology into the US clinical laboratory market,” says Haas, “the feedback from potential customers with knowledge and experience in the shortcomings of current platforms, is consistently positive, demonstrating a clear market opportunity, and crystallizing our regulatory and commercialization plan.”
Dr. Liu invented and patented the core technology of the versatile PlexStation 2080 platform to provide significant reagent and labor savings. “Your Diagnostic Platform Partner” is the company’s motto, and with new leadership and several current collaborations, Plexigen is poised to deliver this economic value to the current laboratory environment.
Plexigen is a privately held diagnostic company focusing on instrumentation and service for a wide array of clinical testing. The company has developed a highly-sensitive 3-D biological microarray, the PlexCube, that overcomes the traditional 2-D array limitations of inflexibility and low throughput. The PlexStation 2080 utilizes an elegant and patented design of stacking a 2-D substrate, called a PlexCard to form a 3-D PlexCube, to economically do large (and small) panels of biomarkers, antibodies, antigens, genes, and/or protein detection, on one instrument. The transformational methodology uses a very small fraction of the detection reagent used on current platforms (e.g., ELISA and other immunoassays), potentially saving high-throughput laboratories millions of dollars in annual expense. The PlexStation 2080 is available for select on-site premarket evaluation and collaboration studies.
Plexigen was incorporated in North Carolina in 1999. The company is located in Cary, North Carolina in the heart of The Research Triangle.
Further information about Plexigen can be found at http://www.plexigen.com/, or contact Bill Haas's office directly at 919.468.5552.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.